GeneDx Holdings Corp. 8-K

What Happened

• On February 23, 2026, GeneDx Holdings Corp. (WGS) filed a Form 8‑K (Item 2.02) stating it issued a press release and will hold a conference call to announce the company's financial results for the year ended December 31, 2025. The press release and the earnings presentation are furnished as Exhibits 99.1 and 99.2 to the filing. The report was signed by Katherine Stueland, Chief Executive Officer.

Key Details

• Filing date: February 23, 2026 (Form 8‑K, Item 2.02).
• Event: Press release and earnings presentation issued; conference call to announce 2025 year‑end results.
• Exhibits: 99.1 = Press Release (dated Feb 23, 2026); 99.2 = Earnings Presentation (dated Feb 23, 2026).
• Signer: Katherine Stueland, CEO, authorized the filing.

Why It Matters

• The 8‑K signals GeneDx is publicly releasing its full-year 2025 earnings and related materials—investors should review the press release and presentation (exhibits) for revenue, earnings, and other performance metrics. The planned conference call provides a chance for management commentary and investor Q&A, which can affect near‑term stock reactions.